

DRUGGABILITY

The LBN is comprehensive contract research facility offering a full suite of *in vivo* & *ex vivo* disease models, service and analysis.

Relatively high throughput screening assays have been set up to screen and validate compounds in clinically relevant models of lung diseases and environmental injury.

The Monash 'LBN' Researchers have extensive experience and clinical expertise in lung physiology, pharmacology and pathology. The LBN team is continuing to develop numerous tools and models that provide a comprehensive and accurate analysis of the utility of potential new lung medicaments.

Clinical expertise also extends to allergy and respiratory medicine as well as access to experts with technical capabilities including lung mechanics, precision lung slicing, laser capture microdissection (LCM) and image analysis.

The end result is to facilitate *druggability* of the compound, to bridge the gap from preliminary work and basic science to clinical trials in humans.

From experience we know this is a long process but experiments in disease models can be planned with very specific endpoints and goals. This means success and progress for the client.

